Jeff Yass’s Avalo Therapeutics AVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-16,500
Closed -$305K – 13484
2026
Q2
$305K Sell
16,500
-146,500
-90% -$2.32M ﹤0.01% 11003
2026
Q1
$2.43M Buy
163,000
+138,700
+571% +$2.17M ﹤0.01% 5720
2025
Q4
$441K Buy
24,300
+10,700
+79% +$181K ﹤0.01% 9096
2025
Q3
$173K Buy
+13,600
New +$117K ﹤0.01% 11138
2022
Q2
– Sell
-5
Closed -$10K – 12846
2022
Q1
$10K Sell
5
-9
-64% -$22.6K ﹤0.01% 12747
2021
Q4
$70K Sell
14
-12
-46% -$72K ﹤0.01% 12376
2021
Q3
$166K Sell
26
-3
-10% -$24.3K ﹤0.01% 11695
2021
Q2
$272K Buy
29
+16
+123% +$134K ﹤0.01% 10985
2021
Q1
$109K Buy
+13
New +$123K ﹤0.01% 11815

Other funds holding AVTX

Jeff Yass's AVTX Position: Q3 2026 in Review

Jeff Yass increased its Avalo Therapeutics (AVTX) stake by 1,689% in Q3 2026, buying an estimated $8.46M and bringing the position to 486,975 shares worth $7.47M. The position accounts for ﹤0.01% of the portfolio, ranked #3778.

Jeff Yass first reported a position in AVTX in Q1 2019 and has held it in 17 quarters since. 148 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.

  • Jeff Yass held 486,975 shares of Avalo Therapeutics worth $7.47M as of Q3 2026.
  • Jeff Yass bought 459,748 Avalo Therapeutics shares in Q3 2026, an estimated $8.46M.
  • Avalo Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #3778 holding.
  • Jeff Yass first reported a position in Avalo Therapeutics in Q1 2019 and has held it in 17 quarters since.
  • 148 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.